EMEA-000234-PIP02-14

Key facts

Invented name
Cervarix
Active substance
  • human papillomavirus type 18 L1 protein
  • human papillomavirus type 16 L1 protein
Therapeutic area
Vaccines
Decision number
P/0008/2015
PIP number
EMEA-000234-PIP02-14
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Prevention of infection by human papillomavirus
Route(s) of administration
Intramuscular use
Contact for public enquiries
GlaxoSmithKline Biologicals SA
Belgium
E-mail: eu.paediatric-plans@gsk.com
Tel. +44 (20) 8966 3220
Fax +44 (20) 8966 2221
Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating
Average
1 rating